David Gill, MD of the Huntsman Cancer Institute presents “Correlation of tumor programmed death ligand-1 (PD-L1) expression and response to treatment with high-dose interleukin-2 (HD IL-2) in metastatic clear cell renal cell carcinoma (mccRCC).” at the 14th International Kidney Cancer Symposium.